A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Carcinoma, Non-Small-Cell Lung|Triple Negative Breast Neoplasms|Squamous Cell Carcinoma of Head and Neck
Interventions: DRUG: Pembrolizumab|DRUG: TAK-676|RADIATION: Image-guided radiation therapy
Sponsor: Takeda